Rockwell Medical, Inc. (RMTI)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 62 | 62 | 73 | 84 | 101 | 69 | 69 | 72 |
| Operating profit | $m | -5 | -5 | ||||||
| Net profit | $m | -31 | -33 | -19 | -8 | -0 | -5 | -5 | -4 |
| EPS reported | $ | -1.50 | -1.39 | ||||||
| Operating cashflow per share | $ | -0.18 | 0.73 | ||||||
| Capex per share | $ | 0.15 | 0.34 | ||||||
| FCF per share | $ | -0.33 | 0.39 | ||||||
| Free cash flow | $m | -1 | 2 | ||||||
| Net debt | $m | -16 | -14 | ||||||
| Book value equity | $m | 37 | 35 | ||||||
| Book value per share | $ | 10.28 | 8.86 | ||||||
| Number of shares | m | 3.6 | 3.96 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.81 | 0.86 | ||||||
| P/S LTM | x | 0.43 | 0.43 | ||||||
| P/FCF LTM | x | -24.98 | 19.48 | ||||||
| EV/EBITDA LTM | x | -15.90 | -13.57 | ||||||
| EV/Sales LTM | x | 0.46 | 0.47 | ||||||
| Earnings Yield LTM | % | -17.71% | -17.33% | ||||||
| FCF Yield | % | -4.00% | +5.13% | ||||||
| Quality | |||||||||
| ROE | % | -14.37% | -14.03% | ||||||
| ROIC | % | -9.49% | -9.23% | ||||||
| Operating margin | % | -6.77% | -6.52% | ||||||
| Gross margin | % | +16.89% | +17.71% | ||||||
| FCF/Sales | % | -1.73% | +2.22% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -31.76% | -31.63% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | -51.74% | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.10 | 0.11 | ||||||
| Net Debt/EBITDA | x | -0.88 | -1.46 | ||||||
| EBIT/Net interest | x | -4.17 | -3.99 | ||||||
| Net debt/market cap | % | +30.30% | +30.78% | ||||||
| Net debt/Equity | x | -0.43 | -0.40 | ||||||
| Gross debt/equity | x | 0.34 | 0.40 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free